FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to a compound of formula (0) or a pharmaceutically acceptable salt thereof. In the formula (0) T1 and T2 represent N; R1 is selected from hydrogen, fluorine and C1-4 hydrocarbyloxy; R2 is selected from hydrogen, fluorine and C1-4 hydrocarbyloxy; R3 is selected from hydrogen, fluorine; M1 is a group of R4, selected from hydrogen and chlorine and M2 is a fragment -A-R7, in which the linking group A and R7 have the values indicated in the claims; R5 is selected from hydrogen, cyano, C1-3 alkyl, chlorine, carboxy and C1-3 alkoxycarbonyl; R6 is hydrogen. Also pharmaceutical compositions containing a compound of formula (0). 
.
EFFECT: proposed compounds inhibit or modulate the activity of Chk-1 kinase and can be used in the treatment of proliferative diseases.
19 cl, 4 tbl, 163 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788174C2 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788163C2 |
| N2-(2-PHENYL)-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND USE THEREOF AS MPS1 INHIBITOR | 2015 |
|
RU2693460C2 |
| COMPOUNDS USED IN PHARMACEUTICS | 2006 |
|
RU2425677C2 |
| PYRAZOLOPYRIMIDINE COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONISTS | 2019 |
|
RU2806758C2 |
| 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | 2016 |
|
RU2736123C1 |
| 3-AMINO-1-ARYLPROPYLINDOLES APPLIED AS INHIBITOR MONOAMINE REUPTAKE | 2005 |
|
RU2382031C2 |
| 3,4-SUBSTITUTED 1H-PIRAZOLE COMPOUNDS AND THEIR APPLICATION AS CYCLIN-DEPENDANT KINASES (CDK) AND MODULATORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | 2004 |
|
RU2408585C2 |
| PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | 2004 |
|
RU2419612C2 |
| HETEROCYCLIC COMPOUND | 2019 |
|
RU2815003C2 |
